The human monoclonal antibody (mAb) HK20 neutralizes a broad spectrum of primary HIV-1 isolates by targeting the highly conserved heptad repeat 1 (HR1) of gp41, which is transiently exposed during HIV-1 entry. Here we present the crystal structure of the HK20 Fab in complex with a gp41 mimetic 5-Helix at 2.3 Å resolution. HK20 employs its heavy chain CDR H2 and H3 loops to bind into a conserved hydrophobic HR1 pocket that is occupied by HR2 residues in the gp41 post fusion conformation. Compared to the previously described HR1-specific mAb D5, HK20 approaches its epitope with a different angle which might favor epitope access and thus contribute to its higher neutralization breadth and potency. Comparison of the neutralization activities of HK20 IgG, Fab and scFv employing both single cycle and multiple cycle neutralization assays revealed much higher potencies for the smaller Fab and scFv over IgG, implying that the target site is difficult to access for complete antibodies. Nevertheless, two thirds of sera from HIV-1 infected individuals contain significant titers of HK20-inhibiting antibodies. The breadth of neutralization of primary isolates across all clades, the higher potencies for C-clade viruses and the targeting of a distinct site as compared to the fusion inhibitor T-20 demonstrate the potential of HK20 scFv as a therapeutic tool.
Vyšlo v časopise: Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41. PLoS Pathog 6(11): e32767. doi:10.1371/journal.ppat.1001195 Kategorie: Research Article prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1001195
1. WalkerLM
BurtonDR
2010 Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Current Opinion in Immunology 22 3 358 66
2. BuonaguroL
TorneselloML
BuonaguroFM
2007 Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 81 10209 10219
3. Karlsson HedestamGB
FouchierRAM
PhogatS
SodroskiJ
2008 The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. 6 143 155
4. WalkerLM
2010 Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22 358 366
5. DalgleishAG
BeverleyPC
ClaphamPR
CrawfordDH
GreavesMF
1984 The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312 763 767
6. KlatzmannD
ChampagneE
ChamaretS
GruestJ
GuetardD
1984 T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312 767 768
7. HuangCC
TangM
ZhangMY
MajeedS
MontabanaE
2005 Structure of a V3-containing HIV-1 gp120 core. Science 310 1025 1028
8. MooreJP
TrkolaA
DragicT
1997 Co-receptors for HIV-1 entry. Curr Opin Immunol 9 551 562
9. BergerEA
MurphyPM
FarberJM
1999 Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17 657 700
10. WeissenhornW
HinzA
GaudinY
2007 Virus membrane fusion. FEBS Lett 581 2150 2155
11. HarrisonSC
2008 Viral membrane fusion. Nat Struct Mol Biol 15 690 698
12. Munoz-BarrosoI
DurellS
SakaguchiK
AppellaE
BlumenthalR
1998 Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 140 315 323
13. FurutaRA
WildCT
WengY
WeissCD
1998 Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 5 276 279
14. MatthewsT
SalgoM
GreenbergM
ChungJ
DeMasiR
2004 Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3 215 225
15. WeissenhornW
DessenA
HarrisonSC
SkehelJJ
WileyDC
1997 Atomic structure of the ectodomain from HIV-1 gp41. Nature 387 426 430
16. ChanDC
FassD
BergerJM
KimPS
1997 Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 263 273
17. CaffreyM
CaiM
KaufmanJ
StahlSJ
WingfieldPT
1998 Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J 17 4572 4584
18. BuzonV
NatrajanG
SchibliD
CampeloF
KozlovMM
2010 Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions. PLoS Pathog 6 e1000880
19. MelikyanGB
MarkosyanRM
HemmatiH
DelmedicoMK
LambertDM
2000 Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151 413 423
20. de RosnyE
VassellR
JiangS
KunertR
2004 Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 78 2627 2631
21. DimitrovAS
JacobsA
FinneganCM
StieglerG
KatingerH
2007 Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 46 1398 1401
22. FreyG
PengH
Rits-VollochS
MorelliM
ChengY
2008 A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A 105 3739 3744
23. MillerMD
GeleziunasR
BianchiE
LennardS
HrinR
2005 A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 102 14759 14764
24. NelsonJD
KinkeadH
BrunelFM
LeamanD
JensenR
2008 Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377 170 183
25. LouisJM
NesheiwatI
ChangL
CloreGM
BewleyCA
2003 Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 278 20278 20285
26. LouisJM
GustchinaE
AnianaA
2005 Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41. J Mol Biol 353 945 951
27. GustchinaE
LouisJM
LamSN
2007 A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol 81 12946 12953
28. GustchinaE
FrischC
YleraF
LechnerA
2009 Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naive human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth. Virology 393 112 119
29. BianchiE
JoyceJG
MillerMD
FinnefrockAC
LiangX
2010 Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 107 23 10655 60
30. RootMJ
KayMS
2001 Protein design of an HIV-1 entry inhibitor. Science 291 884 888
31. LuftigMA
MattuM
Di GiovineP
2006 Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol 13 740 747
32. EckertDM
MalashkevichVN
HongLH
CarrPA
1999 Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99 103 115
33. SiaSK
CochranAG
2002 Short constrained peptides that inhibit HIV-1 entry. Proc Natl Acad Sci U S A 99 14664 14669
34. CortiD
LangedijkJPM
SeamanMS
VanzettaF
2010 Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals. PLoS ONE 5 1 e8805
35. SchibliDJ
WeissenhornW
2006 Class I and class II viral fusion protein structures reveal similar principles in membrane fusion. Mol Membr Biol 21 361 371
36. HamburgerAE
KimS
WelchBD
2005 Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 280 12567 12572
37. StoddartCA
NaultG
GalkinaSA
ThibaudeauK
BakisP
2008 Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem 283 34045 34052
38. SuhreK
SanejouandY-H
2004 ElNemo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement. Nucl Acids Res 32 W610 614
39. MontgomeryDL
WangYJ
LuftigM
SuB
2009 Affinity maturation and characterization of a human monoclonal anti2body against HIV-1 gp41. MAbs 1 462 474
40. GagnonP
HenselF
RichiersiR
2008 Purification of IgM monoclonal antibodies. BioPharm International Supplements Mar 2 2008
41. WildC
OasT
McDanalC
BolognesiD
MatthewsT
1992 A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 89 10537 10541
42. FerrerM
KapoorTM
StrassmaierT
1999 Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 6 953 960
43. VincentN
KoneA
ChanutB
LuchtF
GeninC
2008 Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates. Aids 22 2075 2085
44. FenyoEM
HeathA
DispinseriS
HolmesH
LussoP
2009 International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4 e4505
45. ChoudhryV
HarrisI
SidorovIA
VuB
DimitrovAS
2006 Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun 348 1107 1115
46. MiyauchiK
KimY
LatinovicO
MorozovV
MelikyanGB
2009 HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137 433 444
47. RimskyLT
ShugarsDC
MatthewsTJ
1998 Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72 986 993
48. LuJ
DeeksSG
HohR
BeattyG
KuritzkesBA
2006 Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 43 60 64
49. KilbyJM
HopkinsS
VenettaTM
DiMassimoB
CloudGA
1998 Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4 1302 1307
50. NaiderF
AnglisterJ
2009 Peptides in the treatment of AIDS. Curr Opin Struct Biol 19 473 482
51. HrinR
MontgomeryDL
WangF
CondraJH
AnZ
2008 Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N - and C-terminal heptad repeats of HIV Type 1 gp41. AIDS Res Hum Retroviruses 24 1537 1544
52. StewartKD
SteffyK
HarrisK
HarlanJE
StollVS
2007 Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery. J Comput Aided Mol Des 21 121 130
53. EckertDM
1998 Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J Mol Biol 284 859 865
54. LeslieAGW
1992 Recent changes to the MOSFLM package for processing film and image plate data. Jnt CCP4/ESF-EACMB Newslett Protein Crystallogr 26
55. EvansP
2006 Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62 72 82
56. CCP4 1994 The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50 157 163
57. McCoyAJ
Grosse-KunstleveRW
AdamsPD
WinnMD
StoroniLC
2007 Phaser crystallographic software. J Appl Crystallogr 40 658 674
58. PerrakisA
MorrisR
LamzinVS
1999 Automated protein model building combined with iterative structure refinement. Nat Struct Biol 6 458 463
59. EmsleyP
CowtanK
2004 Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60 2126 2132
60. MurshudovGN
VaginAA
DodsonEJ
1997 Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53 240 255 |
61. LiM
GaoF
MascolaJR
StamatatosL
PolonisVR
2005 Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79 10108 10125
62. LiM
Salazar-GonzalezJF
DerdeynCA
MorrisL
WilliamsonC
2006 Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80 11776 11790
63. ScarlattiG
TresoldiE
BjorndalA
FredrikssonR
ColognesiC
1997 In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 3 1259 1265
64. GornyMK
WilliamsC
VolskyB
ReveszK
CohenS
2002 Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol 76 9035 9045
65. ScarlattiG
AlbertJ
RossiP
HodaraV
BiraghiP
1993 Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 168 207 210
Zvýšte si kvalifikáciu online z pohodlia domova
Nemáte účet? Registrujte sa
Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.
